Neuroblastoma Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight's "Neuroblastoma Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Neuroblastoma pipeline landscape. It covers the Neuroblastoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroblastoma Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Neuroblastoma Pipeline? Click here to explore the therapies and trials making headlines @ Neuroblastoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Neuroblastoma Pipeline Report

* On 31 October 2025, Milton S. Hershey Medical Center conducted a study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.
* On 28 October 2025, Novartis Pharmaceuticals announced a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
* DelveInsight's Neuroblastoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Neuroblastoma treatment.
* The leading Neuroblastoma Companies such as INSYS Therapeutics Inc., Hoffmann-La Roche, Endeavor Biomedicines Inc., Novartis Pharmaceuticals, Daiichi Sankyo, Celgene, Cancer Research UK, Cardiff Oncology, Elicio Therapeutics, Merck, Eli Lilly and Company, Pfizer, Adaptimmune , and others.
* Promising Neuroblastoma Therapies such as Eflornithine, Temozolomide, Irinotecan, DFMO, Racotumomab, Bevacizumab, Temozolomide, Topotecan hydrochloride and others.

Want to know which companies are leading innovation in Neuroblastoma? Dive into the full pipeline insights @ Neuroblastoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Neuroblastoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neuroblastoma Pipeline Report also highlights the unmet needs with respect to the Neuroblastoma.

Neuroblastoma Overview

Neuroblastoma is a rare type of cancer that mostly affects babies and young children. It develops from specialised nerve cells (neuroblasts) left behind from a baby's development in the womb. Neuroblastoma most commonly occurs in 1 of the adrenal glands situated above the kidneys, or in the nerve tissue that runs alongside the spinal cord in the neck, chest, tummy or pelvis. It can spread to other organs, such as the bone marrow, bone, lymph nodes, liver and skin. Neuroblastoma is a type of cancer that primarily affects young children and arises from immature nerve cells. Common signs and symptoms include a lump or mass in the abdomen, chest, or neck, often accompanied by pain or swelling. Other symptoms can include fatigue, loss of appetite, weight loss, and fever.

Neuroblastoma Emerging Drugs Profile

* Hu14.18: Essential Pharma

Hu14.18K322A, commonly referred to as Hu14.18, is a humanized anti-GD2 monoclonal antibody developed by Renaissance Pharma for the treatment of high-risk neuroblastoma (HRNB). In April 2025, Essential Pharma announced that it had completed the acquisition of the Renaissance Pharma Ltd. with its lead asset being Hu14.18K322A (Hu14.18). Currently the drug is in Phase II stage of its clinical trial for the treatment of neuroblastoma.

* 67-Cu-SARTATE: Clarity Pharmaceuticals

67Cu-SARTATE is an emerging theranostic radiopharmaceutical specifically designed for the diagnosis and treatment of high-risk neuroblastoma, a particularly aggressive childhood cancer. This compound utilizes copper-67 (67Cu) as a therapeutic agent, complementing its diagnostic counterpart, copper-64 (64Cu), which is used for imaging. The drug has been granted Rare Pediatric Disease Designation and Orphan Drug Designation for the clinical management of neuroblastoma. Currently the drug is in Phase I/II stage of its clinical trial for the treatment of neuroblastoma.

* Alrizomadlin (APG-115): Ascentage Pharma

APG-115 is a potent, orally bioavailable MDM2 inhibitor that binds to human recombinant MDM2 protein with high affinity. Mechanistically, APG-115 interferes the binding of MDM2 oncoprotein with the tumor suppressor P53 protein, leads to increased P53 and P21 protein expression and trigger P53-mediated apoptosis. In addition to its direct tumor-targeting activity, APG-115 plays an important role in immune modulation through its effects on immune cells, tumor cells and multiple cytokines. Alrizomadlin has been granted Orphan Drug Designations by the U.S. FDA for the treatment of gastric cancer, soft-tissue sarcoma, AML, Retinoblastoma, IIB-IV melanoma and Neuroblastoma. Currently the drug is in Phase I stage of its clinical trial for the treatment of Neuroblastoma.

If you're tracking ongoing Neuroblastoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Neuroblastoma Treatment Drugs [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Neuroblastoma Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Neuroblastoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroblastoma Treatment.
* Neuroblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neuroblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroblastoma market.

Neuroblastoma Companies

INSYS Therapeutics Inc., Hoffmann-La Roche, Endeavor Biomedicines Inc., Novartis Pharmaceuticals, Daiichi Sankyo, Celgene, Cancer Research UK, Cardiff Oncology, Elicio Therapeutics, Merck, Eli Lilly and Company, Pfizer, Adaptimmune, and others.

Neuroblastoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Neuroblastoma Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Neuroblastoma Pipeline Report covers it all - check it out now @ Neuroblastoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Neuroblastoma Pipeline Report

* Coverage- Global
* Neuroblastoma Companies- INSYS Therapeutics Inc., Hoffmann-La Roche, Endeavor Biomedicines Inc., Novartis Pharmaceuticals, Daiichi Sankyo, Celgene, Cancer Research UK, Cardiff Oncology, Elicio Therapeutics, Merck, Eli Lilly and Company, Pfizer, Adaptimmune , and others.
* Neuroblastoma Therapies- Eflornithine, Temozolomide, Irinotecan, DFMO, Racotumomab, Bevacizumab, Temozolomide, Topotecan hydrochloride and others.
* Neuroblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neuroblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Neuroblastoma Treatment landscape in this detailed analysis @ Neuroblastoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Neuroblastoma: Overview
* Neuroblastoma Pipeline Therapeutics
* Neuroblastoma Therapeutic Assessment
* Neuroblastoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Hu14.18: Essential Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Alrizomadlin (APG-115): Ascentage Pharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Neuroblastoma Key Companies
* Neuroblastoma Key Products
* Neuroblastoma- Unmet Needs
* Neuroblastoma- Market Drivers and Barriers
* Neuroblastoma- Future Perspectives and Conclusion
* Neuroblastoma Analyst Views
* Neuroblastoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroblastoma-pipeline-outlook-report-2025-promising-drugs-and-moa-innovations-reshape-future-treatment-approaches-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.